| Literature DB >> 35443646 |
Joan Nankya-Mutyoba1, David Ejalu2, Claude Wandera3, Rachel Beyagira4, Jacinto Amandua4, Emmanuel Seremba5, Kaggwa Mugagga6, Andrew Kambugu3, Alex Muganzi3, Philippa Easterbrook6, Ponsiano Ocama5.
Abstract
INTRODUCTION: The "2for1" project is a demonstration project to examine the feasibility and effectiveness of HBV care integrated into an HIV clinic and service. An initial phase in implementation of this project was the development of a specific training program. Our objective was to describe key features of this integrated training curriculum and evaluation of its impact in the initial cohort of health care workers (HCWs).Entities:
Keywords: Health care workers; Hepatitis B; Knowledge; Uganda
Mesh:
Year: 2022 PMID: 35443646 PMCID: PMC9020110 DOI: 10.1186/s12909-022-03329-3
Source DB: PubMed Journal: BMC Med Educ ISSN: 1472-6920 Impact factor: 3.263
Fig. 1Schema showing pre-training HBV knowledge assessment, education intervention and post-training assessment of health care workers in West Nile region, Uganda
Characteristics of Health Care Workers who participated in the HBV education training in Arua, West-Nile region
| Characteristic | Mean | SD |
|---|---|---|
| 34.3 | 8.3 | |
| Male | 20 | 45.5 |
| Female | 24 | 54.5 |
| 20–29 | 17 | 38.6 |
| 30–39 | 14 | 31.8 |
| 40–49 | 10 | 22.7 |
| 50–59 | 3 | 6.8 |
| Physician/medical officer | 6 | 13.6 |
| Clinical officer | 9 | 20.5 |
| Midwife | 4 | 9.1 |
| Nurse | 8 | 18.2 |
| Lab-technician | 4 | 9.1 |
| Pharmacy technician | 4 | 9.1 |
| Data/records officer | 3 | 6.8 |
| Patient counselors | 4 | 9.1 |
| Community outreach worker | 2 | 4.5 |
| < 5 | 24 | 54.5 |
| 5–10 | 11 | 25.0 |
| > 10 | 9 | 20.5 |
| Arua | 28 | 64.0 |
| Koboko | 16 | 36.0 |
Content of hepatitis B “Training for integration” Curriculum for Health Care Workers in West Nile Region, Uganda
| Module | Module content |
|---|---|
Natural history, epidemiology and transmission of infection | I. Emphasized burden of HIV, of HBV, of dual infection, and similarities between HBV and HIV infection transmission II. The influence of HIV on HBV natural history, and the influence of HBV on HIV natural history |
Laboratory diagnosis | I. Basics of laboratory diagnosis for HBV II. Similar platforms for diagnosis of HIV and HBV (ELISA), III. HIV viral load and HBV viral load IV. Similar transportation systems for samples (the hub system) for viral load samples V. Same processing facility for viral load tests (Central Public Health Laboratories) |
Care and treatment | I. Covered for HBV and HBV-HIV co-infection II. Both being chronic diseases with no cure but life-long care and treatment III. The HIV “test and treat” strategy, versus the HBV treatment strategy that requires additional tests to decide who is eligible for treatment IV. Medications for HBV treatment provided in public hospitals by the Government and ART by both Government and Partners |
Prevention | I. Commonalities between prevention of HIV and of HBV, including preventing mother-to-child HBV transmission II. Community-linkage for continued follow-up and prevention of complications for HBV mono-infected persons III. Community engagement Community networks of HBV (treatment peer support, community groups to have patients’ voice) to be woven into existing structure for HIV Need for continuous monitoring emphasized, and to remain in care Need for raising community awareness, to eliminate erroneous disease perceptions and fight stigma addressed as part of curriculum, through local radio-based programs, where individuals calls-in and have their questions and concerns discussed as part of community engagement |
Cross-cutting issues, rationale, planning and coordination of integration | I. Why integrate? (i)Significant overlap between both infections and the need to offer care for both infections in a well-coordinated care system. (ii) Need for a public health response, to give the widest possible reach for HBV care, treatment and continuous monitoring would be efficiently met through care integration II. HIV as a “high profile” disease (Well-structured clinics all over the country; funded laboratories and pharmacy, strong patient and community networks, clinician task-shifting and data capture services) versus HBV as a “neglected” disease (Runs a silent course, with high levels of stigma and discrimination, lacks all infrastructure, apart from free tenofovir, has insufficient media representation and advocacy among health workers, patients and at political level) III. Leverage on the well-developed infrastructure for HIV to offer HBV services to all who need it IV. Co-planning, training and coordination for integrated HIV and HBV service delivery across the care continuum |
Pre- and post- intervention mean scores of participants’ total knowledge by baseline characteristics
| Characteristic | Pre-test mean score | Post-test mean score | |
|---|---|---|---|
| Male | 29.3 (5.4) | 31.8 (4.0) | |
| Female | 25.5 (4.7) | 29.6 (3.4) | |
| ≤ 30 | 26.6 (5.3) | 29.9 (3.6) | |
| > 30 | 27.9 (5.3) | 31.2 (4.0) | |
| ≤ 5 | 27.9 (5.7) | 31.2 (4.4) | |
| > 5 | 26.6 (5.0) | 29.9 (2.9) | |
| Arua | 26.4 (5.2) | 30.5 (3.7) | |
| Koboko | 28.7(5.4) | 30.7(4.1) | |
Pre- and post-intervention mean scores of HBV knowledge domains
| Knowledge domain | Pre-test mean score | Post-test mean score | |
|---|---|---|---|
| Epidemiology and transmission | 8.5(1.7) | 9.5 (0.8) | |
| Natural history of HBV | 4.0(1.8) | 4.7 (1.6) | |
| Diagnosis of HBV | 2.4(1.1) | 2.5 (1.2) | 0.685 |
| Treatment of HBV | 5.5(1.5) | 7.0 (1.2) | |
| Prevention of HBV | 4.2(1.1) | 4.0 (1.0) | 0.384 |
Pre- and post-test mean scores of participants’ domain-specific knowledge, by sex, age and years in service
| | Male | 20 (45.5%) | 9.0 (1.5) | 9.4(0.9) | |
| Female | 24 (54.5%) | 8.2 (1.8) | 9.5 (0.7) | ||
| | ≤ 30 | 22 (50.0%) | 8.5 (1.5) | 9.3 (0.6) | |
| > 30 | 22 (50.0%) | 8.5 (1.9) | 9.5 (0.9) | ||
| | ≤ 5 | 24 (54.5%) | 8.8 (1.5) | 9.5 (0.8) | |
| > 5 | 20 (45.5%) | 8.2 (1.8) | 9.4 (0.8) | ||
| | Arua | 28 (64.0%) | 8.6 (1.5) | 9.4 (0.8) | |
| Koboko | 16 (36.0%) | 8.4 (1.8) | 9.6 (0.8) | ||
| | Male | 20 (45.5%) | 4.5 (1.5) | 5.2 (1.5) | 0.131 |
| Female | 24 (54.5%) | ||||
| | ≤ 30 | 22 (50.0%) | 4.0 (1.6) | 4.2 (1.4) | 0.535 |
| > 30 | 22 (50.0%) | ||||
| | ≤ 5 | 24 (54.5%) | |||
| > 5 | 20 (45.5%) | 4.1 (1.9) | 4.7 (1.6) | 0.124 | |
| | Arua | 28 (64.0%) | |||
| Koboko | 16 (36.0%) | 4.4 (1.4) | 4.6 (1.5) | 0.628 | |
| | Male | 20 (45.5%) | 2.9 (1.3) | 3.0 (1.2) | 0.649 |
| Female | 24 (54.5%) | 2.0 (0.9) | 2.1 (1.1) | 0.869 | |
| | ≤ 30 | 22 (50.0%) | 2.1 (1.0) | 2.7 (1.2) | 0.589 |
| > 30 | 22 (50.0%) | 2.7 (1.2) | 2.7 (1.3) | 1.000 | |
| | ≤ 5 | 24 (54.5%) | 2.5 (1.1) | 2.7 (1.3) | 0.462 |
| > 5 | 20 (45.5%) | 2.4 (1.1) | 2.3 (1.2) | 0.847 | |
| | Arua | 28 (64.0%) | 2.3 (1.1) | 2.5 (1.2) | 0.312 |
| Koboko | 16 (36.0%) | 2.4 (1.2) | 2.6 (1.3) | 0.509 | |
| | Male | 20 (45.5%) | 6.1 (1.4) | 7.2 (1.0) | |
| Female | 24 (54.5%) | 4.9 (1.4) | 6.8 (1.2) | ||
| | ≤ 30 | 22 (50.0%) | 5.3 (1.8) | 6.9 (1.2) | |
| > 30 | 22 (50.0%) | 5.6 (1.3) | 7.1 (1.1) | ||
| | ≤ 5 | 24 (54.5%) | 5.7 (1.5) | 6.9 (1.3) | |
| > 5 | 20 (45.5%) | 5.1 (1.6) | 7.1 (0.9) | ||
| | Arua | 28 (64.0%) | 5.2 (1.5) | 7.1 (1.1) | |
| Koboko | 16 (36.0%) | 7.1 (1.1) | 6.8 (1.2) | ||
| | Male | 20 (45.5%) | 4.3 (1.2) | 4.3 (0.9) | 0.825 |
| Female | 24 (54.5%) | 4.2 (1.0) | 3.9 (1.0) | 0.397 | |
| | ≤ 30 | 22 (50.0%) | 4.0 (1.0) | 4.1 (1.0) | 0.880 |
| > 30 | 22 (50.0%) | 4.4 (1.1) | 4.0 (0.8) | 0.088 | |
| | ≤ 5 | 24 (54.5%) | 4.3 (1.0) | 4.1 (0.9) | 0.632 |
| > 5 | 20 (45.5%) | 4.2 (1.1) | 4.0 (0.8) | 0.447 | |
| | Arua | 28 (64.0%) | 4.0 (1.1) | 4.1 (0.8) | 0.526 |
| Koboko | 16 (36.0%) | ||||